17年间前列腺癌的临床特征变化

doi:10.3969/j.issn.1000-8535.2018.03.002

广州医药 ›› 2018, Vol. 49 ›› Issue (3): 5-9.DOI: 10.3969/j.issn.1000-8535.2018.03.002

17年间前列腺癌的临床特征变化

曾维威, 谢克基, 韦兴华, 莫灿程, 汤平

广州医科大学附属市一人民医院泌尿外科(广州 510180)

收稿日期:2018-01-08 出版日期:2018-05-20 发布日期:2021-12-01
通讯作者: 汤平, E-mail:879732434@qq.com

Changes in clinical features of inpatients with prostate cancer in the past 17 years

ZENG Weiwei, XIE Keji, WEI Xinghua, MO Cancheng, TANG Ping

Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University,Guangzhou 510180,China

Received:2018-01-08 Online:2018-05-20 Published:2021-12-01

摘要/Abstract

摘要： 目的探讨我院17年间前列腺癌患者的临床特征如发病年龄、前列腺特异性抗原(PSA)、Gleason评分、分期及穿刺阳性率等的变化。方法采用回顾性分析,对广州市第一人民医院2000—2016年泌尿外科1 231例穿刺活检的患者及564例前列腺癌患者资料进行分析,按患者的诊断时间分为A组(2000—2005年)、B组(2006—2009年)、C组(2010—2012年)、D组(2013—2014年)、E组(2015—2016年),对各组的年龄、PSA、Gleason评分、分期及穿刺活检阳性率进行统计学分析,看各组间的各项指标差异是否有统计学意义。结果 5组年龄均值(73.36,73.74,72.05,73.40,72.96岁)、PSA均值(208.95,190.25,173.19,283.54,148.69 μg/L)及穿刺活检阳性率均值(48%,43%,37%,44%,39%)差异均无统计学意义(P均>0.05)。5组Gleason均值为6.80,6.73,7.12,6.93,7.32,A、B组和E组Gleason评分差异有统计学意义(P均<0.05),其余各组Gleason评分差异均无统计学意义(P均>0.05)。TNM分期转化得分5组均值为5.96,6.80,7.05,7.31,6.83, A和C组、D组、E组差异均有统计学意义(P均<0.05),其余各组TNM分期转化得分差异均无统计学意义(P均>0.05)。结论 17年间前列腺癌患者诊断时的年龄、PSA水平及穿刺活检阳性率没有显著变化。

关键词: 前列腺癌, 前列腺癌临床分期, 前列腺特异性抗原, Gleason评分

Abstract: Objective To investigate changes of inpatients with prostate cancer in the last 17 years such as age of onset, prostate specific antigen (PSA), Gleason score, prostate cancer staging and positive rate of prostate biopsy. Methods A retrospective analysis was conducted in 1 231 cases of biopsy patients of urology and 564 patients with prostate cancer who were hospitalized in the First People's Hospital of Guangzhou from 2000 to 2016. According to the time of diagnose. All the patients were divided into five groups: group A(2000-2005),group B(2006-2009),group C(2010-2012), group D(2013-2014)and group E(2015-2016). The age, PSA, Gleason score, staging and positive rate of prostate biopsy were compared to realize whether the indicators of the differences between groups was statistically significant. Results In five groups, means of age, PSA, Gleason score and prostate biopsy positive rate are respectively 73.36,73.74,72.05,73.40,72.96 years; 208.95,190.25,173.19,283.54,148.69 μg/L;6.80,6.73,7.12,6.93,7.32; 5.96,6.80,7.05,7.31,6.83 and 48%,43%,37%,44%,39%. There was no significant difference in age, PSA and positive rate of prostate biopsy (P>0.05). The Gleason scores of group A and group E, group B and group E were statistically significant (P<0.05), while the other groups had no significant differences in Gleason score (P>0.05). There werestatistical significancein TNM staging score between group A and group C,group D, group E(P <0.05),while the other groups had nostatistical significance (P>0.05). Conclusion There are no change of prostate cancer patients in diagnosis of age, PSA levels and positive rate of prostate biopsy in the past 17 years.

Key words: Prostate cancer, Prostate stage, Prostate specific antigen, Gleason score

曾维威, 谢克基, 韦兴华, 莫灿程, 汤平. 17年间前列腺癌的临床特征变化[J]. 广州医药, 2018, 49(3): 5-9.

ZENG Weiwei, XIE Keji, WEI Xinghua, MO Cancheng, TANG Ping. Changes in clinical features of inpatients with prostate cancer in the past 17 years[J]. Guangzhou Medical Journal, 2018, 49(3): 5-9.

参考文献

[1] CENTER M M, JEMAL A, LORTET-TIEULENT J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6): 1079-1092.
[2] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[3] MAIRE A, WILLIAM F, SEAN Altekruse, et al. The Surveillance, Epidemiology, and End Results(SEER)Program and Pathology[J]. Am J Surg pathol, 2016,40(12),e94-102.
[4] 马春光,叶定伟,李长岭,等. 前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J]. 中华外科杂志, 2008, 46(12): 921-925.
[5] GAO X, REN S, LU X, et al. The newer the better? Comparison of the 1997 and 2001 partin tables for pathologic stage prediction of prostate cancer in China[J]. Urol, 2008, 72(5): 1096-1101.
[6] PEYROMAURE M, DEBRE B, MAO K, et al. Management of prostate cancer in China: a multicenter report of 6 institutions[J]. J Urol, 2005, 174(5): 1794-1797.
[7] 叶定伟,朱耀. 中国前列腺癌的流行病学概述和启示[J]. 中华外科杂志, 2015, 53(4): 249-252.
[8] TANG P, SUN L, UHLMAN M A, et al. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades duke university experience[J]. Cancer, 2010, 116(20): 4711-4717.
[9] TANG P, SUN L, UHLMAN M A, et al. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men[J]. BJU Int, 2011, 108(1): 44-48.
[10] LIN Y R, WEI X H, UHLMAN M, et al. PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml(-1) and 10.1-20.0 ng ml(-1): a multicenter study[J]. Asian J Androl, 2015, 17(3): 503-507.
[11] TANG P, CHEN H, UHLMAN M, et al. A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer[J]. Asian J Androl, 2013, 15(1): 129-133.
[12] 那彦群. 中国泌尿外科疾病诊断治疗指南[M]. 北京:人民卫生出版社, 2007: 30-38.
[13] WONG M C, GOGGINS W B, WANG H H, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries[J]. Eur Urol, 2016, 70(5): 862-874.
[14] HOFFMAN R M, MEISNER A L, ARAP W, et al. Trends in united states prostate cancer incidence rates by age and stage, 1995-2012[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(2): 259-263.
[15] JEMAL A, FEDEWA S A, MA J, et al. Prostate cancer incidence and psa testing patterns in relation to USPSTF screening recommendations[J]. JAMA, 2015, 314(19): 2054-2061.
[16] LOEB S, COOPERBERG M R. Early detection of prostate cancer[J]. Urol Clin North Am, 2014, 41(2): xiii.
[17] BOKHORST L P, ZHU X, BUL M, et al. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial[J]. BJU Int, 2012, 110(11): 1654-1660.
[18] 刘俊,胡卫列,宋波,等. 增加穿刺活检针数提高前列腺癌分级准确性的临床研究[J]. 中华泌尿外科杂志, 2009, 30(10)697-699.
[19] TEISHIMA J, MARUYAMA S, MOCHIZUKI H, et al. Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection[J]. Can Urol Assoc J, 2014, 8(5-6): E327-332.

17年间前列腺癌的临床特征变化

Changes in clinical features of inpatients with prostate cancer in the past 17 years

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	张林洋, 朱玲玲, 朱国华. 中医药治疗前列腺癌研究进展[J]. 广州医药, 2021, 52(5): 135-138.
[2]	岑昕贝, 凌济忠, 万跃平, 万颂, 华伟, 江敏耀, 习明. NR3C1表达与前列腺癌生化复发的相关性研究[J]. 广州医药, 2020, 51(4): 22-27.
[3]	缪智雄, 朱旭生. ⁹⁹锝-亚甲基二膦酸盐治疗前列腺癌骨转移疗效观察[J]. 广州医药, 2018, 49(3): 94-96.
[4]	钟思苗, 陈瑞芳, 苏建平, 邹绮嫦, 吴小文. 不同分化程度前列腺癌经直肠超声图像特征观察[J]. 广州医药, 2018, 49(3): 103-105.